Skip to main content
. 2020 Aug 18;55(10):891–902. doi: 10.1097/MCG.0000000000001409

FIGURE 3.

FIGURE 3

Adjusted annual all-cause health care costs from generalized linear model among patients with NAFLD/NASH by liver disease severity stage. aNAFLD/NASH study cohort comprises overall NAFLD/NASH patients until progression to a more severe stage, at which follow-up is censored. bHealth care costs represent the total annual all-cause postindex costs. †P<0.0001 for comparison of CC, DCC, LT, or HCC cohort versus NAFLD/NASH without AdvLD cohort. AdvLD indicates advanced liver diseases; CC, compensated cirrhosis; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplantation; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.